Actualización en Retinopatía del Prematuro-Reference-Cited by-同舟云学术

Actualización en Retinopatía del Prematuro

Published:2022-03-08 Issue:1 Volume:15 Page:23-30
ISSN:2079-4703
Container-title:Highlights of Vitreoretina
language:en
Short-container-title:

Author:

Neria Dra. Paulina Ramírez,Martínez-Castellanos Dra. María Ana,Chimal Dr. Luis Gilberto Pérez,Aguas Dr. Juan Carlos Romo,Vázquez Dr. José Francisco Pérez,Castro Dra. Selene Rodríguez,Desio Dr. Alejandro Ortega

Publisher

Jaypee Brothers Medical Publishing

Subject

General Medicine

Link

https://hov.jphmedical.com/doi/pdf/10.5005/hov-10102-15102

Reference34 articles.

1. Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, Binenbaum G, Blair M, Peter Campbell J, Capone A Jr, Chen Y, Dai S, Ells A, Fleck BW, Good WV, Elizabeth Hartnett M, Holmstrom G, Kusaka S, Kychenthal A, Lepore D, Lorenz B, Martinez-Castellanos MA, Özdek Ş, Ademola-Popoola D, Reynolds JD, Shah PK, Shapiro M, Stahl A, Toth C, Vinekar A, Visser L, Wallace DK, Wu WC, Zhao P, Zin A. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016/j.ophtha.2021.05.031. Epub 2021 Jul 8. PMID: 34247850.

2. Mehta, S. R. et al. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. N. Engl. J. Med. 264, 687–696 (2015).

3. Filippi, L. and Dal Monte, M. A safety review of drugs used for the treatment of retinopathy of prematurity. Expert Opin. Drug Saf. 19, 1409–1418 (2020).

4. Sukgen, E. A. and Koçluk, Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefe's Arch. Clin. Exp. Ophthalmol. 257, 49–55 (2019).

5. Stahl, A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394, 1551–1559 (2019).